GLP1-2U Review

Rank #9 of 10

glp1-2u.com

Evidence confidence: Low

A multi-brand reseller whose retatrutide product page explicitly and falsely claims “FDA Approved” status — the most serious single regulatory-accuracy finding.

What we verified

We independently confirmed that glp1-2u.com prices exclusively in ZAR, uses South African +27 contact formatting, and publishes dated Privacy Policy and Terms of Service pages [51]. The description of a specific retatrutide product listing (Noventra Pharma Retatrutide 32mg) explicitly states “GLP-1 Receptor Agonist | Multi-Dose Injectable Pen | FDA Approved” and lists “Clinical Indications” including “Type 2 Diabetes Management” and “Obesity Treatment: Significant weight reduction (10–15% body weight)” [70]. Retatrutide is not approved by the FDA or any medicines regulator anywhere in the world (see our retatrutide research overview), so this specific claim is false. A homepage banner stated: “Our banking details have changed. Please double-check before making payments to ensure you use the correct account” [51]. The Privacy Policy, Terms of Service, Shipping & Return Policy and shipping-details page are genuinely detailed [84][85][86][87][88], but we noted a minor discrepancy between the delivery fee stated in the Terms of Service (R150) [86] and the Shipping & Return Policy (R170) [87], and between a contact phone number given in the policy pages and the WhatsApp number used site-wide. The homepage's own marketing copy for its self-mix vials also reads “Reconstitute and draw your own dose” [51].

What the vendor claims

GLP1-2U positions itself as a multi-brand marketplace, selling retatrutide-branded products under third-party brand names including “The Clinic,” “Noventra Pharma,” “HD Labs,” “U.P.A.” and “Body Pharm,” in various dosages and formats including pre-filled pens and self-mix vials [51]. At least one specific listing describes its product as “FDA Approved” with named clinical indications, discussed above [70]. Its homepage markets retatrutide primarily through a per-milligram price comparison across its own brands, describing itself as offering the “Best priced retatrutide in SA” [51].

Testing & documentation

Product listings show only generic marketing tags (“lab-tested,” “pharmaceutical-grade,” “clinical-grade”) with no laboratory named and no Certificate of Analysis or identifier given [70][84]. Because this vendor operates as a reseller of several distinct third-party brands, any more specific testing claims would need to be assessed brand-by-brand, which this review did not attempt for every brand sold.

Business transparency

No physical address or business registration was found in the content reviewed, including in its Privacy Policy and Terms of Service [85][86]. Contact is via a site-wide WhatsApp number and an email reference; a different phone number appears in its policy pages.

Shipping

The Shipping & Return Policy and the shipping-details page are both genuinely detailed, covering courier delivery, an order-tracking form, and a stated flat delivery fee of R170 [87][88]. The separate Terms of Service states a flat delivery fee of R150 [86].

Refunds & returns

The Shipping & Return Policy is genuinely detailed: returns are accepted only for sealed, unused items within 7 days of delivery [87].

Website & policies

The Privacy Policy and Terms of Service (both dated 2025) are genuinely detailed documents, not placeholder links: the Privacy Policy references POPIA and names real payment processors (PayFast, PayPal) [85], and the Terms of Service sets out usage terms and a liability disclaimer [86].

Public reputation

We could not locate a dedicated Hellopeter or Trustpilot review page for glp1-2u.com. We are treating this as an absence of accessible evidence, not as a negative signal in itself.

Regulatory & research-use context

No research-use-only or non-medical disclaimer was found on this site; it uses an age-restriction notice instead. More materially, a specific retatrutide product listing explicitly claims “FDA Approved” status and describes named clinical indications for diabetes and obesity treatment [70]. Retatrutide has not been approved by the FDA or any regulator anywhere (see our retatrutide research overview), and general SAHPRA guidance states that compounding unregistered GLP-1-class active ingredients is not permitted under South African medicines law. This is the most direct false regulatory-approval claim found on any vendor's own page. The vendor's own Terms of Service state that products “must be used exactly as instructed and are intended for personal use only,” and that its liability clause discusses “injury” and “side effects” arising from product “use or misuse” [86] — personal-consumption framing in the vendor's own primary legal document. The homepage's own marketing copy for its self-mix vials, “Reconstitute and draw your own dose,” reinforces this [51].

Strengths & limitations

Strengths

  • Detailed, dated (2025) privacy, terms and shipping/returns policies, citing POPIA and naming PayFast and PayPal
  • ZAR-only pricing and South African contact details make its target market clear

Limitations

  • A retatrutide listing claims “FDA Approved” with clinical indications — false: retatrutide is not approved by any regulator
  • No research-use disclaimer; its Terms say products are “intended for personal use only” and discuss side effects from use
  • Homepage says “Reconstitute and draw your own dose” — a direct self-administration instruction
  • Minor slips: R150 vs R170 delivery fee and different phone numbers across policy pages; a “32mg Vial” page with a “10mg” URL
  • Homepage notice says banking details changed; no reason is given
  • Sells retatrutide only under third-party brands (“HD Labs”, “Noventra Pharma”), with no named lab behind “lab-tested” tags
  • Catalogue dominated by steroids, SARMs and PCT; retatrutide marketed on per-mg price, not research framing
  • No address, registration or independent reputation signal found
  • Generic .com domain, not .co.za

Evidence confidence

Low. A specific retatrutide product listing's description explicitly states “FDA Approved” and lists “Clinical Indications” for Type 2 Diabetes Management and Obesity Treatment — claims that are false: retatrutide is not approved by the FDA or any regulator anywhere (see our retatrutide research overview). Its Privacy Policy, Terms of Service and Shipping & Return Policy are all genuinely detailed documents, and its Terms of Service separately describes products as intended for “personal use only.” The homepage also displayed a notice that the vendor's banking details had changed, which we report factually without being able to determine its cause.

Methodology score breakdown

Score breakdown under Methodology v1.2.0.
CriterionWhy this scorePoints
Business Transparency Only a WhatsApp number and a general email reference are published; no address or registration information was found.
5 / 15
Testing & Documentation Disclosure Generic marketing tags (“lab-tested,” “pharmaceutical-grade,” “clinical-grade”) were found on a product listing, but no laboratory is named and no COA or identifier is given.
5 / 15
Independent Verifiability of Testing Claims No named laboratory or identifier exists to independently verify.
0 / 15
Policy Completeness (Shipping, Refunds, Terms, Privacy) The Privacy Policy, Terms of Service and Shipping & Return Policy are all genuinely detailed, dated (2025) documents rather than placeholder links — covering data handling with reference to POPIA, naming real payment processors (PayFast, PayPal), and specific return conditions (sealed/unused items, within 7 days).
15 / 15
Research-Use & Regulatory Framing Clarity No research-use-only disclaimer exists anywhere on the site, and a specific product listing explicitly and falsely claims “FDA Approved” status with medical “Clinical Indications”. The Terms of Service state products are for “personal use only” and discuss “injury” from “use or misuse,” and the homepage's own marketing copy instructs readers to “reconstitute and draw your own dose.”
0 / 10
Public Reputation Signals No dedicated review-platform page was located for this vendor.
0 / 15
Website & Policy Reliability The site and its policy pages functioned normally. A minor discrepancy was noted between the delivery fee stated in the Terms of Service (R150) and the Shipping & Return Policy (R170), and between a contact phone number given in the policy pages and the WhatsApp number used site-wide; this is judged more likely an editorial/formatting slip than a substantive reliability failure, and is not scored as one.
15 / 15
Total40 / 100

Sources for this review

Editorial conclusion

The evidence supports GLP1-2U as a multi-brand reseller whose policy pages are genuinely detailed rather than placeholder links, set against the complete absence of a research-use disclaimer, personal-use language in its own Terms of Service, self-administration marketing copy on its homepage, and, most seriously, a direct, false “FDA Approved” claim with named clinical indications on at least one product listing. The false “FDA Approved” claim remains the single most concerning accuracy finding across every vendor reviewed, and is the primary reason this vendor's score remains well below the sample's higher performers despite genuinely detailed policy pages. From a transparency standpoint, a reader encountering an “FDA Approved” claim for any retatrutide product should treat it as false unless independently reconfirmed at the time of reading.

← Back to the full vendor ranking